Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
IMV’s DPX-Survivac promotes anti-cancer responses and boosts the sensitivity of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to Keytruda (pembrolizumab) combined with chemotherapy, interim data ... Read more
The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more
Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large ... Read more